CEO Daniela Marino, PhD, emphasizes that the Switzlerand based company has received Orphan Drug Designation from the Swissmedic, EMA, and FDA, for its personalized human skin graft.
Daniela Marino, PhD
Advertisement
Articles by Daniela Marino, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
The Emerging Role of Oral Peptide Therapeutics in Dermatology
2
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
3
Rese-cel Data Support Registrational Strategy Across Dermatomyositis, Systemic Sclerosis, Lupus
4
Suneel Chilukuri, MD on the Crucial Role of Barrier Repair and Tailored BPO Therapy
5